AnaptysBio (ANAB) Competitors $17.93 +0.51 (+2.93%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$17.93 0.00 (0.00%) As of 01/31/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ANAB vs. NAMS, MESO, IDYA, AGIO, TARS, IOVA, WVE, BLTE, APGE, and AMPHShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include NewAmsterdam Pharma (NAMS), Mesoblast (MESO), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Wave Life Sciences (WVE), Belite Bio (BLTE), Apogee Therapeutics (APGE), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. NewAmsterdam Pharma Mesoblast IDEAYA Biosciences Agios Pharmaceuticals Tarsus Pharmaceuticals Iovance Biotherapeutics Wave Life Sciences Belite Bio Apogee Therapeutics Amphastar Pharmaceuticals NewAmsterdam Pharma (NASDAQ:NAMS) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership. Do insiders & institutionals have more ownership in NAMS or ANAB? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 33.7% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to NAMS or ANAB? In the previous week, NewAmsterdam Pharma had 7 more articles in the media than AnaptysBio. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 3 mentions for AnaptysBio. NewAmsterdam Pharma's average media sentiment score of 0.91 beat AnaptysBio's score of 0.63 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NAMS or ANAB more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. NewAmsterdam Pharma's return on equity of 0.00% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A AnaptysBio -289.75%-287.94%-37.25% Do analysts rate NAMS or ANAB? NewAmsterdam Pharma currently has a consensus target price of $41.60, suggesting a potential upside of 86.63%. AnaptysBio has a consensus target price of $41.45, suggesting a potential upside of 131.20%. Given AnaptysBio's higher probable upside, analysts plainly believe AnaptysBio is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more risk & volatility, NAMS or ANAB? NewAmsterdam Pharma has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Does the MarketBeat Community prefer NAMS or ANAB? AnaptysBio received 343 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 66.01% of users gave AnaptysBio an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes24100.00% Underperform VotesNo VotesAnaptysBioOutperform Votes36766.01% Underperform Votes18933.99% Which has higher earnings and valuation, NAMS or ANAB? AnaptysBio has higher revenue and earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$14.09M146.16-$176.94MN/AN/AAnaptysBio$17.16M31.80-$163.62M-$6.08-2.95 SummaryNewAmsterdam Pharma beats AnaptysBio on 9 of the 16 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$530.07M$6.88B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E RatioN/A4.5158.9914.21Price / Sales31.80320.231,258.0383.19Price / CashN/A73.5045.9637.70Price / Book5.405.275.124.71Net Income-$163.62M$136.98M$111.17M$224.24M7 Day Performance6.41%-0.59%2.37%-0.17%1 Month Performance35.42%0.18%3.19%0.60%1 Year Performance-26.06%7.68%24.69%20.43% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio3.7906 of 5 stars$17.93+2.9%$41.45+131.2%-24.0%$530.07M$17.16M0.00100NAMSNewAmsterdam Pharma3.1898 of 5 stars$22.80-3.4%$41.60+82.5%+8.9%$2.10B$14.09M0.004MESOMesoblast0.7116 of 5 stars$17.90-2.0%$13.50-24.6%+1,044.3%$2.05B$5.90M0.0080Analyst UpgradeShort Interest ↑News CoverageIDYAIDEAYA Biosciences4.1034 of 5 stars$23.63+0.0%$53.67+127.1%-44.1%$2.04B$23.39M-10.1480Short Interest ↑AGIOAgios Pharmaceuticals4.0097 of 5 stars$34.47+0.0%$56.33+63.4%+52.0%$1.97B$26.82M3.03390Short Interest ↑TARSTarsus Pharmaceuticals0.9381 of 5 stars$51.17+4.9%$56.00+9.4%+97.4%$1.96B$17.45M-13.4350IOVAIovance Biotherapeutics4.2873 of 5 stars$6.19-1.0%$23.00+271.9%-24.3%$1.88B$1.19M-4.14500Analyst ForecastNews CoverageWVEWave Life Sciences4.4765 of 5 stars$12.12+0.9%$22.22+83.4%+167.8%$1.85B$113.31M-10.94240Positive NewsBLTEBelite Bio3.4096 of 5 stars$58.51-1.5%$96.33+64.7%+33.6%$1.80BN/A-52.6010Short Interest ↓Analyst RevisionPositive NewsAPGEApogee Therapeutics2.6253 of 5 stars$40.08-0.5%$89.71+123.9%+23.5%$1.80BN/A-16.5291AMPHAmphastar Pharmaceuticals4.7683 of 5 stars$36.89+1.1%$60.33+63.5%-34.7%$1.77B$644.40M12.311,761Short Interest ↑ Related Companies and Tools Related Companies NewAmsterdam Pharma Competitors Mesoblast Competitors IDEAYA Biosciences Competitors Agios Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Iovance Biotherapeutics Competitors Wave Life Sciences Competitors Belite Bio Competitors Apogee Therapeutics Competitors Amphastar Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANAB) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANAB Stock Alerts